Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma

New England Journal of Medicine

Volumn 338, Issue 18, 1998, Pages 1265-1271

  Gleave, Martin E ^a,j   Elhilali, Mostafa ^b   Fradet, Yves ^c   Davis, Ian ^d   Venner, Peter ^e   Saad, Fred ^f   Klotz, Laurence H ^g   Moore, Malcolm J ^h   Paton, Virginia ⁱ   Bajamonde, Alex ⁱ   Bell, David ^k   Ernst, Scott ^l   Ramsey, Ernest ^m   Chin, Joe ⁿ   Morales, Alvaro ^o   Martins, Heidi ^p   Sanders, Coree ⁱ  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e CROSS CANCER INSTITUTE   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ GENENTECH INC   (United States)

^j VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^k DALHOUSIE UNIVERSITY   (Canada)

^l TOM BAKER CANCER CENTRE   (Canada)

^m UNIVERSITY OF MANITOBA   (Canada)

ⁿ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^o QUEEN S UNIVERSITY   (Canada)

^p BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FEVER; HEADACHE; HUMAN; INFARCTION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEPHRECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON-GAMMA, RECOMBINANT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 7144255510     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199804303381804     Document Type: Article

References (39)

1. Cancer facts & figures -1996. Atlanta: American Cancer Society, 1996.
2. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310-3.
3. Yagoda A. Chemotherapy ot renal cell carcinoma: 1983-1989. Semin Urol 1989;7:199-206.
4. Pyrhonen S, Salminen E, Lehtonen T, et al. Recombinant interferon alfa-2a with vinblastine vs vinblastine alone in advanced renal cell carcinoma: a phase III study. Proc Am Soc Clin Oncol 1996;15:244A. abstract.
5. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Urol 1983;10:422-30.
6. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989;63:128-31.
7. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12:206-12.
8. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992;148:1247-8.
9. Proleukin. Emeryville, Calif: Cetus Oncology, May 1992 (package insert).
10. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
11. Rosenberg SA, Yang JC, Topalian SI, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2. JAMA 1994;271:907-13.
12. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-81.
13. Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J Natl Cancer Inst 1990;82:143-6.
14. Taneja SS, Pierce W, Figlin R, Belldegrun A. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Urology 1995;45: 911-24.
15. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 1990;50:4190-4.
16. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interteron alpha in metastatic renal cell carcinoma. J Clin Oncol 1985;3:1522-8.
17. Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anri-interferon antibody formation. J Clin Oncol 1988;6:1604-10.
18. Wirth MP Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20:283-95.
19. Otto U, Conrad S, Schneider AW, Klosterhalfen H. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma: results of a phase II trial. Arzneimittelforschung 1988;38:1658-60.
20. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod 1987;6:20-7.
21. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma. Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma: summary of two collaborative studies. Cancer 1987;60:929-33.
22. Rinehart JJ, Malspeis L, Young D, Neidhart JA. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma. J Biol Response Mod 1986;5:300-8.
23. Wagstaff J, Smith D, Nelmes P, Loynds P, Crowther D. A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours. Cancer Immunol Immunother 1987;25:54-8.
24. Paulnock DM, Havlin KA, Storer BM, Spear GT, Sielaff KM, Borden EC. Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma. J Interferon Res 1989;9: 457-73.
25. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as a marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989;27:81-141.
26. Antonelli G, Amicucci P, Cefaro A, Ausiello C, Malavasi F, Dianzani F, Mechanism of human interferon-gamma production: involvement of β-2-microglobulin. Cell Immunol 1988;115:156-64.
27. Aulitzky W, Gastl G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of IFN-γ. J Clin Oncol 1989;7:1875-84.
28. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol 1994;152:841-5.
29. "Exact" analysis of a four-fold table. In: Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981:24-6.
30. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980:70-81.
31. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
32. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
33. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509-16.
34. Maluish AE, Urba WJ, Longo DL, et al. The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 1988;6:434-45.
35. Oliver RDT, Miller RM, Mehta A, Barnett MJ. A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol Biother 1988;1: 14-20.
36. Kerbl K, Pauer W. Spontaneous regression of osseous metastasis in renal cell carcinoma. Aust N Z J Surg 1993;63:901-3.
37. Omland H, Fossa SD. Spontaneous regression of cerebral and pulmonary metastases in renal cell carcinoma. Scand J Urol Nephrol 1989;23:159-60.
38. Davis SD, Koizumi JH, Pitts WR. Spontaneous regression of pulmonary metastases from renal cell carcinoma. Urology 1989;33:141-4.
39. McLeod DG, Skoog SJ. Spontaneous regression of renal cell carcinoma: myth or reality? In: Javadpour N, ed. Cancer of the kidney. New York: Thieme-Stratton, 1984:149-58.